56.80
전일 마감가:
$57.46
열려 있는:
$56.84
하루 거래량:
1.06M
Relative Volume:
1.79
시가총액:
$1.68B
수익:
$232.39M
순이익/손실:
$-26.79M
주가수익비율:
-52.57
EPS:
-1.0804
순현금흐름:
$4.41M
1주 성능:
+0.92%
1개월 성능:
+3.03%
6개월 성능:
-6.19%
1년 성능:
+169.32%
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
ANAB
Anaptysbio Inc
|
56.80 | 1.68B | 232.39M | -26.79M | 4.41M | -1.0804 |
|
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Greenhaven Road Investment Management, L.P.'s AnaptysBio Inc(ANAB) Holding History - GuruFocus
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup - ChartMill
U.S. Earnings Preview: After Market Close Aug. 18 - Moomoo
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control - Yahoo Finance
Bank of America Corp DE Boosts Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio earnings ahead: First results as royalty company By Investing.com - Investing.com Canada
AnaptysBio earnings ahead: First results as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
AnaptysBio (ANAB) Holds Steady at $56.09: Key Levels to WatchNew Listing Stocks - vinanet.vn
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A - Stock Titan
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio Announces Results of 2026 Annual Stockholders Meeting Voting - Kalkine Media
AnaptysBio (ANAB) Climbs 4.33% to $57.87 as Biotech Momentum BuildsETF NAV Deviation - Vinanet
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings? - Sahm
Price-Driven Insight from (ANAB) for Rule-Based Strategy - Stock Traders Daily
AnaptysBio (ANAB) Rallies 3.36% as Biotech Momentum Builds Toward Key ResistanceGolden Cross - dars.gov.et
AnaptysBio (ANAB) awards CEO 53,334 performance stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO - Stock Titan
AnaptysBio Inc (ANAB) Stock News Today - TradingKey
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada
ANAB Q2'26 Earnings: EPS estimate is (0.13) USD - TradingView
AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a 59% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
AnaptysBio (ANAB) Climbs 3.4% to $56.61, Testing Key Resistance Near $59.44Volume Oscillator - vinanet.vn
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
ANAB Q2'26 Earnings: revenue estimate is 17.33M USD - TradingView
AnaptysBio Enters Key Post-Trial Phase in Tesaro Dispute - The Globe and Mail
Arrowstreet Capital Limited Partnership Sells 67,624 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) Projected to Post Earnings on Wednesday - MarketBeat
Eversept Partners LP Decreases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AnaptysBio Inc (ANAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AnaptysBio, Inc. Revenue Breakdown – NASDAQ:ANAB - TradingView
ANAB|AnaptysBio Inc|Price:56.610|Chg%:+1.840 - TradingKey
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
First Light Asset Management LLC Decreases Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio Inc (ANAB) Cash Flow - TradingKey
AnaptysBio Inc (ANAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ANAB|AnaptysBio Inc|Price:53.486|Chg%:-0.124 - TradingKey
ANAB|AnaptysBio Inc|Price:54.150|Chg%:-0.760 - TradingKey
TradingKey - TradingKey
AnaptysBio, Inc. $ANAB Shares Sold by Granahan Investment Management LLC - MarketBeat
ANAB|AnaptysBio Inc|Price:58.470|Chg%:+2.450 - TradingKey
AnaptysBio Inc (ANAB) Income Statement - TradingKey
Anaptysbio, Inc Net Worth (2026) - GuruFocus
Affinity Asset Advisors LLC Boosts Position in AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Buys New Shares in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 5.6%Here's What Happened - MarketBeat
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):